Moving the needle on chronic GVHD of the lung

In this issue of Blood Advances, Sharifi et al 1 share the results of their phase 1 STOP-BOS trial evaluating the antifibrotic oral small molecule pirfenidone for bronchiolitis obliterans syndrome (BOS), the principal form of pulmonary chronic graft-versus-host disease (cGVHD) following hematopoietic cell transplantation (HCT).They demonstrate in patients with established BOS that pirfenidone is well tolerated and slows disease progression or even improves lung function.